Eli Lilly and Company
$ 927.03
2.55%
17 Apr - close price
- Market Cap 829,709,287,000 USD
- Current Price $ 927.03
- High / Low $ 929.99 / 917.80
- Stock P/E 40.32
- Book Value 29.66
- EPS 22.99
- Next Earning Report 2026-04-30
- Dividend Per Share $6.00
- Dividend Yield 0.66 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 1.01 %
- 52 Week High 1132.06
- 52 Week Low 620.46
About
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Analyst Target Price
$1209.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-30 | 2025-08-07 | 2025-05-01 | 2025-02-06 | 2024-10-30 | 2024-08-08 | 2024-04-30 | 2024-02-06 | 2023-11-02 | 2023-08-08 | 2023-04-27 |
| Reported EPS | 7.54 | 7.02 | 6.31 | 3.34 | 5.32 | 1.18 | 3.92 | 2.58 | 2.49 | 0.1 | 2.11 | 1.62 |
| Estimated EPS | 7.17 | 6.37 | 5.59 | 3.54 | 5.0668 | 1.47 | 2.6 | 2.46 | 2.22 | -0.13 | 1.98 | 1.73 |
| Surprise | 0.37 | 0.65 | 0.72 | -0.2 | 0.2532 | -0.29 | 1.32 | 0.12 | 0.27 | 0.23 | 0.13 | -0.11 |
| Surprise Percentage | 5.1604% | 10.2041% | 12.8801% | -5.6497% | 4.9972% | -19.7279% | 50.7692% | 4.878% | 12.1622% | 176.9231% | 6.5657% | -6.3584% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 7.52 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-10 | 2024-06-10 | 2024-03-08 | 2023-12-08 |
| Amount | $1.73 | $1.5 | $1.5 | $1.5 | $1.5 | $1.3 | $1.3 | $1.3 | $1.3 | $1.13 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LLY
2026-04-20 04:21:41
West Pharmaceutical, a leader in injectable drug packaging, is well-positioned for growth due to increasing demand for biologics and vaccines. The company's specialized delivery systems make it indispensable to major drugmakers, and its focus on proprietary technologies and global manufacturing ensures steady demand and strong margins. Investors can evaluate whether West's niche leadership translates to reliable returns amid ongoing healthcare spending trends and its strategic expansion into high-growth segments like cell and gene therapies.
2026-04-20 02:10:00
Novartis AG is focusing on high-value, innovative pharmaceuticals in oncology, immunology, and cardiovascular disease, with key products like Kisqali and Pluvicto driving revenue. The company's strategic shift and R&D investments aim to deliver sustained growth and navigate challenges like patent cliffs and biosimilar competition. Investors are watching to see if Novartis' pipeline can maintain its strong growth trajectory.
2026-04-20 02:09:15
Nektar Therapeutics (US6354171056) presents a high-risk, high-reward opportunity for investors in immuno-oncology, focusing on cytokine engineering to enhance immune responses without toxicity. The company's pipeline is centered on NKTR-255, an engineered IL-15 agonist, with strategic partnerships providing validation and funding. Despite clinical trial risks and competitive pressures, analysts see Nektar as a potential turnaround play, emphasizing the value of its platform and combination potential with approved PD-1 inhibitors.
2026-04-20 02:09:05
Evotec SE partners with major pharmaceutical companies for drug discovery, operating a fee-for-service, milestone, and royalty-based model. Its integrated platform, spanning target identification to clinical candidates, aims to accelerate drug development. The article explores whether Evotec's strategy provides sufficient upside for investors, considering its business model, competitive landscape, U.S. market relevance, risks, and analyst perspectives.
2026-04-20 01:45:02
Amgen Inc. is strategically positioning itself in the competitive biotechnology landscape by focusing on high-demand obesity treatments, alongside its existing strengths in inflammation and oncology. The company's innovative drug pipeline, including candidates like MariTide for obesity, and its established business model with blockbuster drugs, offer potential for significant revenue growth and a resilient investment for U.S. and global investors. While facing risks from clinical trial outcomes, biosimilar competition, and legislative changes, analysts generally view Amgen positively due to its robust pipeline and dividend reliability.
2026-04-19 22:38:03
Eli Lilly is reportedly in advanced negotiations to acquire Kelonia Therapeutics for over $2 billion, according to The Wall Street Journal. This acquisition would strengthen Eli Lilly's oncology pipeline, particularly in hematology, and diversify its growth beyond its current focus on obesity and diabetes drugs. The deal highlights Eli Lilly's strategy of using its strong cash flow for accelerated acquisitions in key therapeutic areas like oncology.
